TDP-43 Peptide Detection via LC-MS/MS for ALS Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing TDP-43 proteinopathy, particularly in biofluids like cerebrospinal fluid or serum, face challenges due to low amounts of pathological TDP-43, non-specific antibody binding, and limited availability of antibodies that distinguish normal full-length TDP-43 from pathological truncated C-terminal fragments, leading to inconsistent results.
Innovation Solution
The development of a method using biochemical techniques, specifically LC-MS/MS to analyze insoluble proteins from post-mortem tissues, identifying signature peptides of TDP-43 species for diagnosing and monitoring TDP-43 proteinopathy, including the use of isotope-labeling and parallel reaction monitoring to quantify these peptides and differentiate between conditions like ALS, AD, and healthy controls.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If ELISA with commercial antibodies is used to measure pathological TDP-43 in cerebrospinal fluid or serum, then the method is simple and can be performed in biofluids, but the results are inconsistent due to non-specific binding and low amounts of pathological TDP-43
Solution Approach 1:
The invention changes the detection parameters by using targeted mass spectrometry with isotope-labeled peptides and specific fragmentation patterns instead of traditional ELISA. This allows specific detection of pathological TDP-43 forms (N-terminal truncated fragments) in biofluids by monitoring characteristic peptide masses and fragmentation, thereby improving measurement consistency while maintaining applicability to biofluid samples
Solution Approach 2:
The invention introduces isotope-labeled internal standards as intermediaries to quantify pathological TDP-43 peptides. These labeled peptides serve as reference points that co-elute with endogenous peptides but can be distinguished by mass, allowing accurate quantification despite the low abundance of pathological forms in complex biofluid matrices
2Adaptability or versatility
If antibodies are used to detect TDP-43 in biofluids, then the detection can be performed in complex matrices like cerebrospinal fluid, but the antibodies show non-specific binding to immunoglobulins and limited availability
Solution Approach 1:
The invention replaces the antibody-based recognition system with a mass spectrometry-based detection system. Instead of relying on antibodies that bind to TDP-43 epitopes (which causes non-specific binding), the method uses mass-to-charge ratio measurement and characteristic fragmentation patterns to specifically identify and quantify pathological TDP-43 peptides, thereby eliminating non-specific binding issues while maintaining applicability to biofluids
3Measurement precision
If immunoblotting of insoluble protein fractions from post mortem tissue is used, then pathological TDP-43 can be detected with a characteristic signature, but the method is limited to insoluble fractions and cannot be reproduced in biofluids
Solution Approach 1:
The invention segments the TDP-43 protein into characteristic peptide fragments through targeted proteolysis (e.g., using chymotrypsin). By detecting specific peptide segments (such as N-terminal truncated fragments) rather than the whole protein, the method can detect pathological forms in both insoluble tissue fractions and soluble biofluids, thereby improving versatility while maintaining detection accuracy
Solution Approach 2:
The invention extracts and isolates specific pathological TDP-43 peptide sequences from complex samples using targeted proteolytic digestion and mass spectrometry. By taking out and measuring only the diagnostic peptide segments (such as C-terminal fragments resulting from N-terminal truncation), the method achieves high detection accuracy in tissue samples and successfully reproduces detection in biofluids where complete proteins may not be accessible
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for accurate discrimination of ALS from other neurodegenerative diseases, providing high sensitivity and specificity in diagnosing TDP-43 proteinopathy, monitoring its progression, and determining prognosis, with potential for identifying susceptible subjects to specific therapies.
Implementation Method 1
LC-MS/MS to identify signature peptides of the TDP-43 species
Implementation Method 2
LC-MS/MS to identify signature peptides of the TDP-43 species
Implementation Method 3
synthesized with a isotope-label isotope tag (heavy) for absolute quantification of corresponding endogenous TDP-43 peptides (light) by parallel reaction monitoring (PRM)
Data Source
AI summary
The invention relates to the diagnosis of a condition characterised by TDP-43 proteinopathy by mass spectrometry using one or more signature peptides of TDP-43 species.